Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071388 | 0.90 | GPR119 (0.49) | GPR119PDE4BTACR1ENPP2 | |
| SCHEMBL3061079 | 0.90 | GPR119 (0.48) | GPR119PDE4BTACR1ENPP2 | |
| SCHEMBL3072614 | 0.89 | GPR119 (0.47) | GPR119PDE4BSCN9ATACR1ENPP2 | |
| SCHEMBL3067284 | 0.89 | GPR119 (0.48) | GPR119PDE4BTACR1ENPP2 | |
| SCHEMBL3078429 | 0.88 | GPR119 (0.47) | GPR119PDE4BTACR1ENPP2 | |
| SCHEMBL3072978 | 0.87 | GPR119 (0.47) | GPR119PDE4BSCN9AENPP2 | |
| SCHEMBL3059539 | 0.87 | PDE4B (0.52) | GPR119PDE4BTACR1 | |
| SCHEMBL16887152 | 0.87 | GPR119 (0.52) | GPR119PDE4B | |
| SCHEMBL3084820 | 0.87 | PDE4B (0.46) | GPR119PDE4B | |
| SCHEMBL3073170 | 0.87 | PDE4B (0.47) | GPR119PDE4BTACR1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | GPR119 729/4885PDE4B 312/4885DPP4 133/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | GPR119 729/4885PDE4B 312/4885DPP4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.